Actinium Pharmaceuticals (NYSE:ATNM) Receives Buy Rating from HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 163.16% from the stock’s previous close.

Separately, Wall Street Zen cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Actinium Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.00.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.52 on Tuesday. The stock has a market capitalization of $47.42 million, a P/E ratio of -1.09 and a beta of -0.27. The company’s 50-day simple moving average is $1.52 and its two-hundred day simple moving average is $1.36. Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $8.64.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC increased its holdings in Actinium Pharmaceuticals by 25.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares in the last quarter. Creative Financial Designs Inc. ADV increased its holdings in Actinium Pharmaceuticals by 42.7% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after acquiring an additional 27,222 shares in the last quarter. Sei Investments Co. purchased a new stake in Actinium Pharmaceuticals in the 4th quarter worth approximately $62,000. JPMorgan Chase & Co. boosted its stake in Actinium Pharmaceuticals by 804.5% in the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock worth $156,000 after purchasing an additional 110,141 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Actinium Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).